Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Oseltamivir

Preparation Calculator

USE IF: Suspected or confirmed influenza in a patient who meets treatment or prophylaxis criteria — start as soon as practical; reconcile renal function and treatment vs prophylaxis intent.

AVOID IF: Known hypersensitivity; substituting prophylaxis schedule for treatment (or vice versa); using antiviral alone as a substitute for deterioration workup when complications are suspected.

Oseltamivir

Neuraminidase inhibitor — anti-influenza

AdultPediatricInfluenzaERWardClinicIDHigh-yield

Indication

Influenza treatment (early preferred) • Post-exposure prophylaxis (protocol) — regimens differ

At a glance

INDICATIONS (CORE USE)

- Treatment of influenza (outpatient, ED, ward, including many hospitalized / high-risk patients when indicated) - Post-exposure prophylaxis in selected patients / settings (separate regimen from treatment)

ADULT DOSE (STANDARD)

Treatment (adult / adolescent): - 75 mg PO BID for 5 days Prophylaxis: - 75 mg PO once daily — duration per exposure / institutional protocol Renal impairment: adjust per CrCl / eGFR table (label / pharmacy) Do not interchange treatment and prophylaxis schedules

MAX DOSE

Treatment: fixed 5-day course at dose tier for renal function — not “PRN escalation” Prophylaxis: duration and dose tier per protocol — not the treatment BID schedule

Route

PO (capsule or oral suspension)

PEDIATRIC DOSE

Weight-based / protocol-based only

Do not miss

Must-not-miss safety points

Major warning

- Start early when indicated; severe / hospitalized / high-risk patients may still benefit when started later — do not withhold solely on time alone without clinical judgment - Treatment and prophylaxis are NOT the same regimen (dose, frequency, duration) - Renal impairment → mandatory dose / schedule adjustment per label or institutional table - Does NOT replace evaluation for bacterial coinfection, secondary pneumonia, or clinical deterioration - Pregnancy: oral oseltamivir preferred when antiviral treatment is indicated (per current guidance / OB)

Indications

Primary

  • Treatment of influenza (including severe / hospitalized / high-risk when antiviral indicated)

Secondary

  • Post-exposure prophylaxis in selected patients / settings (institution- or public-health–directed)

Important

  • Clearly separate treatment intent from prophylaxis intent — dosing and duration differ
  • Antiviral does not replace clinical monitoring for complications or bacterial coinfection

Dosing

STANDARD (ADULT PO)

Treatment (adult / adolescent): - 75 mg PO BID for 5 days Prophylaxis: - 75 mg PO once daily (duration per exposure / protocol)

ADULT DOSE

Treatment: 75 mg BID × 5 days in normal renal function — reduce dose / extend interval per renal tier table when CrCl reduced Prophylaxis: 75 mg QD — renal-adjusted per label; duration per protocol (household / outbreak / occupational context)

PEDIATRIC DOSE

Weight-based dosing only — pediatric reference or institutional pathway

MAX DOSE

Course length and daily dose capped by indication and renal tier — verify label for reduced renal function

Practical Note

- Oral suspension when swallowing capsules is difficult - Never run prophylaxis QD schedule as if it were treatment BID - Recheck eGFR / CrCl before finalizing dose in AKI or fluid shifts

Warnings

Clinical warnings

  • Nausea / vomiting common — support hydration; consider timing with food per tolerance
  • Renal impairment increases active metabolite exposure — adjust dose / interval
  • Neuropsychiatric events reported rarely; severe influenza itself alters mental status — broaden differential
  • Worsening hypoxia, focal findings, prolonged fever, or sepsis pattern → reassess for bacterial coinfection / complications — antiviral is not a substitute for escalation

Contraindications

  • Known hypersensitivity to oseltamivir or product components

Drug interactions

  • Few clinically significant pharmacokinetic interactions at usual doses
  • Live attenuated intranasal influenza vaccine: spacing / avoidance per current immunization guidance when both are relevant

Special populations

Pediatrics

Weight-based / protocol-based only

Pregnancy

Pregnancy: oral oseltamivir preferred when antiviral treatment is indicated — coordinate with OB / ID per local guidance.

Lactation

present in milk in low amounts; risk–benefit with feeding plan when treatment needed.

Renal impairment

Dose / interval adjustment required when CrCl or eGFR reduced — use label or institutional renal dosing table.

Hepatic impairment

Severe hepatic impairment: follow product labeling; routine mild–moderate hepatic disease less central than renal for dose choice.

Elderly

Higher likelihood of reduced renal clearance — verify CrCl / eGFR tier; treat when indicated despite age alone.

Administration

- Start as soon as indicated after decision to treat or provide prophylaxis - Capsule or oral suspension per ability to swallow - Keep treatment (BID Ă— 5 d) vs prophylaxis (QD per protocol) schedules clearly separated in orders and patient instructions

Monitoring

  • Monitor: - Clinical response (fever trajectory, respiratory status, mentation, intake) - Hydration and GI tolerance - Renal function when dosing adjustments depend on CrCl / eGFR - Signs of complication or deterioration (hypoxia, focal chest exam, sepsis)
  • Recheck: - If symptoms worsen at 24–48h on therapy — reassess for secondary bacterial infection or need for escalation; do not continue blindly - If high-risk, hospitalized, or severe illness — closer nursing / vitals / labs per pathway - If renal function changes mid-course — adjust dose per table
  • Hold if:
    - Severe intolerance (risk–benefit with alternative supportive care)
    - Hypersensitivity
    - Clinical deterioration despite therapy — escalate evaluation; antiviral continuation is not automatic

Overdose / toxicity

Clinical Picture

Usually GI-predominant; nausea, vomiting; generally mild with acute overdose

Immediate Actions

- Supportive care - Hydration / antiemesis as indicated - No specific extracorporeal removal role in routine overdose

Antidote

None specific

Decontamination

Acute massive ingestion: supportive care; toxicology consult if refractory vomiting or wide differential.

Escalation

ICU if intractable symptoms or alternative serious diagnosis identified.

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield

  • Treatment (BID Ă— 5 d) ≠ prophylaxis (QD per protocol)
  • Start early; severe / hospitalized / high-risk may still benefit if started later

Clinical

  • Do not let influenza diagnosis delay recognition of bacterial coinfection or complications
  • Verify renal tier before writing outpatient or inpatient orders

Safety

  • Most avoidable error = forgetting renal dose adjustment

Pharmacy Tool

Preparation Calculator

Oseltamivir 15 mg/mL oral suspension — from capsule

suspension · oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

- Oral prodrug converted to active metabolite - Active metabolite exposure rises in renal impairment (drives renal dosing)

Mechanism of action

- Neuraminidase inhibition → reduced viral release / spread from infected cells

Common brand names

Saudi Arabia

Tamiflu, Oseltamivir

Global

(placeholder — verify local formulation)

Common trade names are curated examples only — formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

Global data (no country-specific data available)

  • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
  • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • WHO / national influenza treatment guidelines
  • CDC influenza antiviral guidance (where applicable)
  • FDA / SFDA product labeling (Tamiflu) — renal dosing tables